In experiments involving lung cancer gene mice treated with low-dose Apatinib in combination with PD-L1 inhibitors, it was observed that the concurrent administration of low-dose Apatinib and anti-PD-L1 significantly delayed tumor growth. This evidence concerns the gene CD274 and lung carcinoma.